Spain Diabetes Drugs and Devices Market Size & Share Analysis - Growth Trends & Forecasts (2025 - 2030)

Spain's diabetes drugs and devices market segmented by drugs (insulin, oral anti-diabetic drugs, non-insulin injectable drugs, and combination drugs), and devices (management devices, insulin pumps, insulin pens, syringes, cartridges, and jet injectors, and monitoring devices, self-monitoring blood and continuous glucose monitoring). The report offers the value (in USD) and volume (in unit) for the above segments.

Spain Diabetes Drugs and Devices Market Size & Share Analysis - Growth Trends & Forecasts (2025 - 2030)

Spain Diabetes Drugs and Devices Market Size

Spain Diabetes Drugs and Devices Market Summary
Study Period 2019 - 2030
Base Year For Estimation 2024
Forecast Data Period 2025 - 2030
Historical Data Period 2019 - 2023
CAGR 7.00 %

Major Players

Spain Diabetes Drugs and Devices Market Major Players

*Disclaimer: Major Players sorted in no particular order

Compare market size and growth of Spain Diabetes Drugs and Devices Market with other markets in Healthcare Industry

Biotechnology

Pharmaceuticals

Healthcare IT

Medical Devices

Animal Health

Device Drug Combination

Spain Diabetes Drugs and Devices Market Analysis

The Spain Diabetes Drugs and Devices Market is expected to register a CAGR of greater than 7% during the forecast period.

According to WHO, Spain has administered 102,258,825 vaccine doses as of 25 June 2022. Baseline hyperglycemia significantly predicts all-cause mortality in non-severe COVID-19 patients, regardless of diabetes history. On October 25, the government declared a state of emergency after clinical trials resumed after about four months of easing certain restrictions. This included partial lockdown measures with movement restrictions until May 9, 2021. The COVID-19 pandemic in Spain has forced the government to introduce new laws and restrictions to stop the spread of the virus. Lockdowns have proven to be an effective approach to reducing the risk of infection. For the above reasons, the expansion of the examination market in Spain is predicted.

Insulin drugs are important in treating type 1 diabetes (T1D). Examples of such drugs are insulin drugs. These devices are associated with improved glycemic control and reduced hypoglycemia. In pharmaceuticals, the insulin category holds a significant market share. Worldwide, he has over 100 million people using insulin, including all type 1 diabetics and 10-25% of type 2 diabetics. Insulin production is very demanding, and only a few insulin manufacturers are on the market. Therefore, there is fierce competition among these manufacturers, who constantly strive to meet their patients' needs by providing the highest quality insulin. Medical devices (T1D) are one of the key components in the treatment of type 1 diabetes. Devices include insulin pumps, continuous glucose monitors (CGM), and blood glucose meters. These devices lead to better blood sugar control and less hypoglycemia.

Thus, the above factors are expected to drive market growth over the forecast period.

Spain Diabetes Drugs and Devices Industry Overview

Manufacturers have constantly innovated to survive in the market. Large companies such as Abbott and Medtronic have made numerous mergers, acquisitions, and partnerships to gain market dominance while adhering to organic growth strategies. The manufacturers of insulin delivery devices are spending a huge amount on the R&D of the devices. For example, Novo Nordisk partnered with Abbott Diabetes Care, which may also assist to enable insulin statistics to be shared between Novo Nordisk-connected insulin pens and digital fitness equipment well suited to the FreeStyle Libre portfolio of products. Mega Blockbuster Lantus, manufactured with the aid of Sanofi, led the basal insulin field.

Spain Diabetes Drugs and Devices Market Leaders

  1. Medtronics

  2. Roche

  3. NovoNordisk

  4. Sanofi

  5. Omnipod

  6. *Disclaimer: Major Players sorted in no particular order
Spain Diabetes Drugs and Devices Market Concentration
Need More Details on Market Players and Competiters?
Download PDF

Spain Diabetes Drugs and Devices Market News

  • November 2022: The Eversense E3 continuous glucose monitor (CGM) was approved by the FDA and it received a CE Mark approval in Europe for people with diabetes aged 18 and older.
  • March 2022: Novartis announced that the European Commission (EC) approved Beovu (brolucizumab) 6 mg for the treatment of visual impairment due to diabetic macular edema (DME). The EC decision applied to all 27 European Union (EU) member states, including Spain, as well as Iceland, Norway, and Liechtenstein.

Table of Contents

1. INTRODUCTION

  • 1.1 Study Assumptions and Market Definition
  • 1.2 Scope of the Study

2. RESEARCH METHODOLOGY

3. EXECUTIVE SUMMARY

4. MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Dynamics
    • 4.2.1 Market Drivers
    • 4.2.2 Market Restraints
  • 4.3 Porter's Five Forces Analysis
    • 4.3.1 Bargaining Power of Suppliers
    • 4.3.2 Bargaining Power of Consumers
    • 4.3.3 Threat of New Entrants
    • 4.3.4 Threat of Substitute Products and Services
    • 4.3.5 Intensity of Competitive Rivalry

5. Market Segmentation (Market Size by Value - USD)

  • 5.1 Devices
    • 5.1.1 Monitoring Devices
    • 5.1.1.1 Self-monitoring Blood Glucose Devices
    • 5.1.1.2 Continuous Blood Glucose Monitoring
    • 5.1.2 Management Devices
    • 5.1.2.1 Insulin Pump
    • 5.1.2.2 Insulin Syringes
    • 5.1.2.3 Insulin Cartridges
    • 5.1.2.4 Disposable Pens
  • 5.2 Drugs
    • 5.2.1 Oral Anti-Diabetes Drugs
    • 5.2.2 Insulin Drugs
    • 5.2.3 Combination Drugs
    • 5.2.4 Non-Insulin Injectable Drugs

6. Market Indicators

  • 6.1 Type-1 Diabetes Population
  • 6.2 Type-2 Diabetes Population

7. COMPETITIVE LANDSCAPE

  • 7.1 Company Profiles
    • 7.1.1 Novo Nordisk
    • 7.1.2 Medtronic
    • 7.1.3 Insulet
    • 7.1.4 Tandem
    • 7.1.5 Ypsomed
    • 7.1.6 Novartis
    • 7.1.7 Sanofi
    • 7.1.8 Eli Lilly
    • 7.1.9 Abbottt
    • 7.1.10 Roche
    • 7.1.11 Astrazeneca
    • 7.1.12 Dexcom
    • 7.1.13 Pfizer
  • *List Not Exhaustive
  • 7.2 Company Share Analysis

8. MARKET OPPORTUNITIES AND FUTURE TRENDS

**Subject to Availability
**Competitive Landscape covers- Business Overview, Financials, Products and Strategies, and Recent Developments.
You Can Purchase Parts Of This Report. Check Out Prices For Specific Sections
Get Price Break-up Now

Spain Diabetes Drugs and Devices Industry Segmentation

A few of individuals with type 1 and type 2 diabetes can benefit from using a CGM. Those who would benefit the most are individuals that have trouble reaching and maintaining target blood glucose levels. CGMs are especially useful if they frequently have lows and aren't aware of when they occur (hypoglycemia unawareness). Spain diabetes drugs and devices market segmented by drugs (insulin, oral anti-diabetic drugs, non-insulin injectable drugs, and combination drugs), and devices (management devices, insulin pumps, insulin pens, syringes, cartridges, and jet injectors, and monitoring devices, self-monitoring blood and continuous glucose monitoring). The report offers the value (in USD) and volume (in unit) for the above segments

Devices Monitoring Devices Self-monitoring Blood Glucose Devices
Continuous Blood Glucose Monitoring
Management Devices Insulin Pump
Insulin Syringes
Insulin Cartridges
Disposable Pens
Drugs Oral Anti-Diabetes Drugs
Insulin Drugs
Combination Drugs
Non-Insulin Injectable Drugs
Need A Different Region or Segment?
Customize Now

Frequently Asked Questions

What is the current undefined size?

The undefined is projected to register a CAGR of greater than 7% during the forecast period (2025-2030)

Who are the key players in undefined?

Medtronics, Roche, NovoNordisk, Sanofi and Omnipod are the major companies operating in the undefined.

What years does this undefined cover?

The report covers the undefined historical market size for years: 2019, 2020, 2021, 2022, 2023 and 2024. The report also forecasts the undefined size for years: 2025, 2026, 2027, 2028, 2029 and 2030.

Spain Diabetes Drugs and Devices Industry Report

Statistics for the 2025 Spain Diabetes Drugs and Devices market share, size and revenue growth rate, created by Mordor Intelligence™ Industry Reports. Spain Diabetes Drugs and Devices analysis includes a market forecast outlook for 2025 to 2030 and historical overview. Get a sample of this industry analysis as a free report PDF download.